Literature DB >> 15947370

FDA evaluation of antimicrobials: subgroup analysis.

John H Powers, Daphne Lin, David Ross.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15947370     DOI： 10.1378/chest.127.6.2298

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  5 in total

1.  Increasing consumption of MRSA-active drugs without increasing MRSA in German ICUs.

Authors:  Elisabeth Meyer; Frank Schwab; Barbara Schroeren-Boersch; Petra Gastmeier
Journal:  Intensive Care Med       Date:  2011-08-20       Impact factor: 17.440

Review 2.  Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.

Authors:  John H Powers
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Allan J Walkey; Max R O'Donnell; Renda Soylemez Wiener
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

4.  Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Aisling R Caffrey; Brian J Quilliam; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 5.  Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.

Authors:  Mathias W Pletz; O Burkhardt; T Welte
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.